Zacks analysts issued an updated research report on Allergan stating the company's latest acquisitions of LifeCell and Zeltiq reaffirmed its commitment to acquisitions.
Here's what you should know:
1. Zacks analysts believe Allergan is actively reworking its portfolio through strategic acquisitions.
2. Zacks believes Allergan's sale of Anda last year, has marked the drug maker as a "branded biopharmaceutical leader." Allergan can build around its branded segments and use proceeds to buy back shares, pay down debt and further push its acquisitions in those areas.
3. Allergan's Botox, Linzess, Viberzi and Vraylar all have strong public demand resulting in equally strong sales.
4. Zacks is "optimistic" about the company's future, but worried by upcoming patent challenges to several of Allergan's products. Zacks expects a generic of Namenda XR, to treat the symptoms of moderate-to-severe Alzheimer's disease, could launch in 2017.